[Asia Economy Reporter Ji Yeon-jin] LegoChem Bio announced on the 27th that it has acquired a patent related to 'Antibody-Drug Conjugate (ADC),' a next-generation targeted anticancer agent.
The patent is titled COMPOUNDS COMPRISING SELF-IMMOLATIVE GROUP and covers a proprietary linker technology that enables effective release of anticancer drugs within cancer cells.
The company explained, "By improving the chemical structure of existing linkers, the in vivo stability and drug release of ADCs containing them have been dramatically enhanced, increasing the efficacy of ADC therapeutics while minimizing side effects."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
